California-based Ligand Pharmaceuticals Incorporated is at the forefront of developing new technologies that help pharmaceutical companies discover and develop medicines globally. The biopharmaceutical company has a stellar portfolio of commercial programs, including Kyprolis and Evomela for the treatment of multiple myeloma, Veklury for moderate or severe COVID-19, and Teriparatide injection product for osteoporosis, among others. Of note is Pneumosil, a game-changing conjugate vaccine that fights pneumococcal pneumonia among children. Ligand Pharmaceuticals also offers Rylaze to treat acute lymphoblastic leukemia, Nexterone for arrhythmia, and Zulresso for postpartum depression. The company's partnerships with major pharmaceutical players such as Amgen, Merck, and Pfizer, as well as Gilead Sciences and Baxter International, have enabled Ligand Pharmaceuticals to expand its offerings, making it a force to be reckoned with in the biopharmaceutical industry. Additionally, the company sells Captisol materials, contributing to its overall success. Since its inception in 1987, Ligand Pharmaceuticals has remained steadfast in its mission to transform the pharmaceutical landscape through innovation and strategic partnerships.
Ligand Pharmaceuticals's ticker is LGND
The company's shares trade on the NASDAQ stock exchange
They are based in San Diego, California
There are 11-50 employees working at Ligand Pharmaceuticals
It is ligand.com
Ligand Pharmaceuticals is in the Healthcare sector
Ligand Pharmaceuticals is in the Biotechnology industry
The following five companies are Ligand Pharmaceuticals's industry peers: